PMID- 34238735
OWN - NLM
STAT- MEDLINE
DCOM- 20210712
LR  - 20231103
IS  - 1673-4254 (Print)
IS  - 2663-0842 (Electronic)
IS  - 1673-4254 (Linking)
VI  - 41
IP  - 6
DP  - 2021 Jun 20
TI  - [Puerarin alleviates insulin resistance in type 2 diabetic mice by modulating 
      fetuin B-AMPK/ACC signaling pathway in the liver].
PG  - 839-846
LID - 10.12122/j.issn.1673-4254.2021.06.05 [doi]
AB  - OBJECTIVE: To explore the role of fetuin B-AMPK/ACC signaling pathway in 
      mediating the effect of puerarin on hepatic insulin resistance in mice with type 
      2 diabetes mellitus (T2DM). OBJECTIVE: Forty C57BL/6J mouse models of T2DM 
      induced by high-fat diet and intraperitoneal injection of streptozotocin were 
      randomized into diabetic model (HFD) group and 3 puerarin groups for treatment 
      with low-, moderate- and high- dose puerarin (50, 100 and 200 mg/kg, 
      respectively), with another 10 mice fed a normal diet as the control group. After 
      treatment for 8 weeks, the mice were examined for fasting blood glucose (FBG), 
      fasting insulin (FINS), liver triglycerides (TG), cholesterol (TC) and free fatty 
      acids (FFA) levels. The expression of fetuin B in the liver was detected by 
      immunohistochemistry. RT-qPCR was used to detect the expressions of fetuin B, 
      AMPK, and ACC mRNA in the liver, and the protein expressions of fetuin B, AMPKalpha1, 
      ACC, P-AMPKalphaT183/T172, and P-ACC S79 were determined with Western blotting. 
      OBJECTIVE: Treatment with moderate- and high-dose puerarin significantly lowered 
      TG, TC, FFA and FBG levels in diabetic mice (P < 0.01). Puerarin at all the 3 
      doses significantly lowered FINS and HOMA-IR of the mice (P < 0.01). In diabetic 
      mice, hepatic expressions of fetuin B and ACC mRNA increased and AMPK mRNA 
      decreased significantly (P < 0.01); the protein expressions of fetuin B and ACC 
      increased while those of AMPKalpha1, P-AMPKalphaT183/T172 and P-ACC S79 decreased 
      significantly (P < 0.01). Puerarin dose-dependently inhibited the mRNA and 
      protein expressions of fetuin B and ACC, increased AMPK mRNA and protein 
      expressions of AMPKalpha1, P-AMPKalphaT183/ T172, and P-ACC S79, and lowered fetuin B 
      content in the liver of diabetic mice (P < 0.01). OBJECTIVE: Puerarin alleviates 
      insulin resistance and improves glucolipid metabolism in T2DM mice by modulating 
      hepatic fetuin B-AMPK/ACC signaling pathway.
FAU - Gao, J
AU  - Gao J
AD  - Graduate School, Shanghai University of Traditional Chinese Medicine, Shanghai 
      201203, China.
AD  - Cooperation Research Center of Shanghai University of Traditional Chinese 
      Medicine//Department of Endocrinology, Traditional Chinese Medicine Hospital of 
      Jiading District, Shanghai 201899, China.
FAU - Liu, M
AU  - Liu M
AD  - Cooperation Research Center of Shanghai University of Traditional Chinese 
      Medicine//Department of Endocrinology, Traditional Chinese Medicine Hospital of 
      Jiading District, Shanghai 201899, China.
FAU - Guo, Z
AU  - Guo Z
AD  - Cooperation Research Center of Shanghai University of Traditional Chinese 
      Medicine//Department of Endocrinology, Traditional Chinese Medicine Hospital of 
      Jiading District, Shanghai 201899, China.
FAU - Hu, C
AU  - Hu C
AD  - Cooperation Research Center of Shanghai University of Traditional Chinese 
      Medicine//Department of Endocrinology, Traditional Chinese Medicine Hospital of 
      Jiading District, Shanghai 201899, China.
FAU - Feng, Z
AU  - Feng Z
AD  - Cooperation Research Center of Shanghai University of Traditional Chinese 
      Medicine//Department of Endocrinology, Traditional Chinese Medicine Hospital of 
      Jiading District, Shanghai 201899, China.
FAU - Yan, J
AU  - Yan J
AD  - Cooperation Research Center of Shanghai University of Traditional Chinese 
      Medicine//Department of Endocrinology, Traditional Chinese Medicine Hospital of 
      Jiading District, Shanghai 201899, China.
LA  - chi
PT  - Journal Article
PL  - China
TA  - Nan Fang Yi Ke Da Xue Xue Bao
JT  - Nan fang yi ke da xue xue bao = Journal of Southern Medical University
JID - 101266132
RN  - 0 (Fetuin-B)
RN  - 0 (Insulin)
RN  - 0 (Isoflavones)
RN  - EC 2.7.11.31 (AMP-Activated Protein Kinases)
RN  - Z9W8997416 (puerarin)
SB  - IM
MH  - AMP-Activated Protein Kinases/genetics/metabolism
MH  - Animals
MH  - *Diabetes Mellitus, Experimental/drug therapy
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Diet, High-Fat/adverse effects
MH  - Fetuin-B
MH  - Insulin
MH  - *Insulin Resistance
MH  - Isoflavones
MH  - Liver/metabolism
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Signal Transduction
PMC - PMC8267996
OTO - NOTNLM
OT  - AMPK/ACC
OT  - fetuin B
OT  - glucolipid metabolism
OT  - insulin resistance
OT  - puerarin
EDAT- 2021/07/10 06:00
MHDA- 2021/07/13 06:00
PMCR- 2021/06/20
CRDT- 2021/07/09 06:09
PHST- 2021/07/09 06:09 [entrez]
PHST- 2021/07/10 06:00 [pubmed]
PHST- 2021/07/13 06:00 [medline]
PHST- 2021/06/20 00:00 [pmc-release]
AID - nfykdxxb-41-6-839 [pii]
AID - 10.12122/j.issn.1673-4254.2021.06.05 [doi]
PST - ppublish
SO  - Nan Fang Yi Ke Da Xue Xue Bao. 2021 Jun 20;41(6):839-846. doi: 
      10.12122/j.issn.1673-4254.2021.06.05.